Neoplasms, Glandular and Epithelial  >>  goserelin acetate  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
goserelin acetate / Generic mfg.
TARGET, NCT00589472: Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

Completed
2
19
US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Therapeutic Conventional Surgery, Vorinostat, L-001079038, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
06/10
06/10
NCT01120236: Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
211
US, Canada
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Pharmacological Study
National Cancer Institute (NCI)
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
06/15
08/17

Download Options